Antares Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>AP</div>
ATRS -- USA Stock  

USD 3.91  0.01  0.26%

Antares Pharma Receivables Turnover is relatively stable at the moment as compared to the past year. Antares Pharma reported last year Receivables Turnover of 5.27. As of 03/02/2021, Inventory Turnover is likely to grow to 5.66, while Revenue Per Employee is likely to drop slightly above 699.7 K. While some of us are becoming more passionate about healthcare space, it makes sense to sum up Antares Pharma in greater detail. We will cover the possibilities of making Antares Pharma into a steady grower in April. Here I will also expose some primary fundamental factors affecting Antares Pharma's services, and outline how it will impact the outlook for investors this year.
Published over a month ago
View all stories for Antares Pharma | View All Stories
What are the odds of Antares Pharma to fall in April?
The company reported the previous year's revenue of 143.3 M. Net Income was 9.51 M with profit before overhead, payroll, taxes, and interest of 73.39 M. The company has Profit Margin (PM) of 6.64 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 9.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.09.

How important is Antares Pharma's Liquidity

Antares Pharma financial leverage refers to using borrowed capital as a funding source to finance Antares Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Antares Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Antares Pharma's total debt and its cash.

How Antares utilizes its cash?

To perform a cash flow analysis of Antares Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Antares Pharma is receiving and how much cash it distributes out in a given period. The Antares Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Antares Pharma Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Antares Pharma reported last year Net Cash Flow from Operations of 21.32 Million

A Deeper Perspective

Antares Pharma holds a total of one hundred sixty-six million six hundred seventy thousand outstanding shares. 30% of Antares Pharma outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Breakdown

Retail Investors
48.56%
Insiders
7.49%
Institutions
43.95%
Retail Investors48.56
Insiders7.49
Institutions43.95

The case for Antares Pharma fall maybe to hold

The skewness is down to 0.5 as of today. Antares Pharma currently demonstrates below-average downside deviation. It has Information Ratio of 0.22 and Jensen Alpha of 0.67. However, we advise investors to further question Antares Pharma expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Antares Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Antares Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Bottom Line

While some other entities within the medical instruments & supplies industry are still a little expensive, even after the recent corrections, Antares Pharma may offer a potential longer-term growth to retail investors. While some retail investors may not share our view, we believe it may be a good time to increase your existing holdings in Antares as the risk-reward trade off is appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Antares Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Antares Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com